To date, there are sparingly few reports describing the targeted delivery of STING agonists,70, 71 with most employing surface-decorated nanoparticles for CDN delivery.72–74 Our albumin hitchhiking nanobody approach offers several potential advantages including plug-and-play programmability, precise and site-selective ligation of STING agonists, and a smaller size that has been reported to increase improve tumor penetration, a limitation of nanoparticles and full-length antibodies in tumors with dense stroma.75–77. Here, STING1 is linked to neoplasm.